208 related articles for article (PubMed ID: 6149194)
1. Butofilolol pharmacokinetics in chronic renal insufficiency.
Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of butofilolol (CAFIDE) after repeated oral administration in man.
Houin G; Barre J; Jeanniot JP; Ledudal P; Cautreels W; Tillement JP
Int J Clin Pharmacol Res; 1984; 4(3):175-83. PubMed ID: 6149195
[TBL] [Abstract][Full Text] [Related]
3. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
Balant L; Gorgia A; Marmy A; Tschopp JM
Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
[TBL] [Abstract][Full Text] [Related]
4. Consequences of renal insufficiency on the hepatic clearance of some drugs.
Balant LP; Dayer P; Fabre J
Int J Clin Pharmacol Res; 1983; 3(6):459-74. PubMed ID: 6147317
[TBL] [Abstract][Full Text] [Related]
5. [Comparative pharmacokinetics of the beta-1 receptor blookader celiprolol after a single oral administration in subjects with health kidneys and in patients with impaired renal function].
Schmidt P; Takacs F; Pittner H; Minar E; Balcke P; Zazgornik J; Deutsch E
Wien Klin Wochenschr; 1985 Sep; 97(18):729-32. PubMed ID: 2866633
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
7. Elimination of nadolol by patients with renal impairment.
Herrera J; Vukovich RA; Griffith DL
Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):227S-231S. PubMed ID: 37878
[TBL] [Abstract][Full Text] [Related]
8. A study of practolol elimination in all grades of chronic renal failure.
Kaye CM; Kumana CR; Franklin DA; Baker LR
Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):83-8. PubMed ID: 1165145
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of norfloxacin in chronic renal failure.
Arrigo G; Cavaliere G; D'Amico G; Passarella E; Broccali G
Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
[TBL] [Abstract][Full Text] [Related]
10. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
[TBL] [Abstract][Full Text] [Related]
12. Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new beta-adrenergic blocking agent. Pharmacokinetic studies of carteolol in man.
Morita S; Iinuma M; Kido M; Sakuragi S; Kohri H; Nishino H
Arzneimittelforschung; 1977; 27(12):2380-3. PubMed ID: 23800
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of dibekacin in patients with chronic renal impairment].
Viotte G; Leroy A; Godin M; Fillastre JP
Nouv Presse Med; 1982 Nov; 11(46):3414-8. PubMed ID: 7155849
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
Kowalsky SF; Echols RM; Parker MA
Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cicletanine in patients with impaired renal function.
Jungers P
Drugs Exp Clin Res; 1988; 14(2-3):189-94. PubMed ID: 3416723
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nicotine in kidney failure.
Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
